ATG16L2功能变异预测NSCLC根治性放疗后放射性肺炎及预后
研究在393例接受根治性放疗的北美NSCLC患者中,检测四个自噬相关基因的9个功能性SNP,分析其与放射性肺炎及生存结局的关联。发现ATG16L2 rs10898880 CC基因型患者无局部复发生存、无进展生存和总生存更好,但严重放射性肺炎风险更高;该变异可能影响ATG16L2表达。
要点
- ATG16L2 rs10898880 CC基因型与NSCLC根治性放疗后更好LRFS、PFS和OS相关。
- 同一致死基因型CC携带者发生严重放射性肺炎的风险较AA/AC基因型升高。
- 该SNP可能通过调控ATG16L2基因表达发挥功能,需更大前瞻性研究验证。
核心结论
- ATG16L2 rs10898880可能预测NSCLC根治性放疗后的放射性肺炎、LRFS、PFS和OS。
研究设计与样本
- 在393例接受根治性放疗的北美NSCLC患者中,对四个自噬相关基因(ATG2B、ATG10、ATG12、ATG16L2)的9个潜在功能性SNP进行基因分型。
- 采用多变量Cox比例风险回归分析SNP与RP、LRFS、PFS和OS的关联。
主要发现
- ATG16L2 rs10898880 CC变异基因型患者较AA/AC基因型患者LRFS更好(校正HR=0.59,95%CI 0.45-0.79,p=0.0004)。
- CC基因型患者PFS更好(校正HR=0.64,95%CI 0.48-0.84,p=0.002)。
- CC基因型患者OS更好(校正HR=0.64,95%CI 0.48-0.86,p=0.003)。
- CC基因型患者发生严重RP风险更高(校正HR=1.80,95%CI 1.04-3.12,p=0.037)。
- 功能分析提示rs10898880 C变异等位基因调控ATG16L2基因表达。
临床怎么用
- 该SNP或可用于NSCLC根治性放疗患者的放射性肺炎风险分层及预后评估。
- 携带CC基因型者生存预后较好但需警惕严重放射性肺炎,提示个体化监测。
局限性
- 研究为回顾性分析,样本为北美人群,结论需更大前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Autophagy not only plays an important role in the progression of cancer but is also involved in tissue inflammatory response. However, few published studies have investigated associations between functional genetic variants of autophagy-related genes and radiation pneumonitis (RP) as well as clinical outcomes in patients with NSCLC after definitive radiotherapy. METHODS: We genotyped nine potentially functional single-nucleotide polymorphisms (SNPs) in four autophagy-related genes (autophagy related 2B gene [ATG2B], autophagy related 10 gene [ATG10], autophagy related 12 gene [ATG12], and autophagy related 16 like 2 gene [ATG16L2]) in 393 North American patients with NSCLC treated by definitive radiotherapy and assessed their associations with RP, local recurrence-free survival (LRFS), progression-free survival (PFS), and overall survival (OS) in multivariable Cox proportional hazard regression analyses. RESULTS: We found that patients with the ATG16L2 rs10898880 CC variant genotype had a better LRFS, PFS, and OS (adjusted hazard ratio = 0.59, 0.64, and 0.64; 95% confidence interval: 0.45-0.79, 0.48-0.84, and 0.48-0.86; p = 0.0004, 0.002, and 0.003, respectively), but a greater risk for development of severe RP (adjusted hazard ratio = 1.80, 95% confidence interval: 1.04-3.12, p = 0.037) than did patients with AA/AC genotypes. Further functional analyses suggested that the ATG16L2 rs10898880 C variant allele modulated expression of the ATG16L2 gene. CONCLUSION: This is the first report that one potentially functional SNP rs10898880 in ATG16L2 may be a predictor of RP, LRFS, PFS, and OS in patients with NSCLC after definitive radiotherapy. Additional larger, prospective studies are needed to confirm these findings.
引用
- Wen J, Liu H, Wang L, et al. Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol. 2018. PMID: 29454863. doi:10.1016/j.jtho.2018.01.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。